Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C.

Vigani AG, Macedo de Oliveira A, Tozzo R, Pavan MH, Gonçales ES, Fais V, Gonçales NS, Gonçales FL.

J Viral Hepat. 2011 Apr;18(4):e91-8. doi: 10.1111/j.1365-2893.2010.01385.x. Epub 2010 Oct 25.

PMID:
20969676
2.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

3.

Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.

Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.

J Womens Health (Larchmt). 2015 Feb;24(2):159-64. doi: 10.1089/jwh.2014.4796. Epub 2015 Feb 3.

PMID:
25682817
4.

Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P.

Arthritis Rheum. 2006 Nov;54(11):3696-706.

5.

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA.

Enferm Infecc Microbiol Clin. 2013 Aug-Sep;31(7):424-9. doi: 10.1016/j.eimc.2012.12.004. Epub 2013 Feb 28.

PMID:
23453582
6.
7.

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.

Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.

J Viral Hepat. 2008 Aug;15(8):591-9. doi: 10.1111/j.1365-2893.2008.00988.x. Epub 2008 May 14.

PMID:
18482284
8.

Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.

Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P.

Blood. 2010 Jul 22;116(3):326-34; quiz 504-5. doi: 10.1182/blood-2009-10-248518. Epub 2010 May 3.

9.
10.

Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.

Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiò MA, Chironna M, Sansonno D.

Blood. 2010 Jul 22;116(3):343-53. doi: 10.1182/blood-2009-10-245878. Epub 2010 Mar 22.

11.

The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.

Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC.

Braz J Infect Dis. 2015 Jan-Feb;19(1):15-22. doi: 10.1016/j.bjid.2014.08.002. Epub 2014 Sep 1.

12.

[The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].

Fan XH, Wang LF, Liu LC, Yao Y, Shan Y, Lu HY, Wu CH, Xu XY, Wei L.

Zhonghua Gan Zang Bing Za Zhi. 2011 Oct;19(10):721-5. doi: 10.3760/cma.j.issn.1007-3418.2011.10.001. Chinese.

PMID:
22409840
13.

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.

Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Viral Hepat. 2010 May;17(5):336-44. doi: 10.1111/j.1365-2893.2009.01182.x. Epub 2009 Aug 12.

PMID:
19678893
14.

Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.

Elefsiniotis IS, Pavlidis C, Ketikoglou I, Koutsounas S, Scarmeas N, Pantazis KD, Moulakakis A, Tsianos EV.

Eur J Intern Med. 2008 Jun;19(4):266-70. doi: 10.1016/j.ejim.2007.06.014. Epub 2008 Jan 15.

PMID:
18471675
15.

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.

Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ; Brazilian HCV-Related Advanced Fibrosis Study Group.

Braz J Infect Dis. 2014 Jan-Feb;18(1):48-52. doi: 10.1016/j.bjid.2013.05.007. Epub 2013 Sep 20.

16.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

17.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

18.

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.

Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, El Hoseiny M, Zalata K, Abdel-Hamid M, Fontanet A, Mohamed MK, Esmat G.

Liver Int. 2008 Sep;28(8):1112-9. doi: 10.1111/j.1478-3231.2008.01750.x. Epub 2008 Apr 7.

PMID:
18397226
19.

Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.

Ioannou GN, Scott JD, Yang Y, Green PK, Beste LA.

Aliment Pharmacol Ther. 2013 Dec;38(11-12):1373-84. doi: 10.1111/apt.12524. Epub 2013 Oct 16.

20.

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.

Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM; FIPSE LT-HIV Investigators.

J Hepatol. 2015 Jan;62(1):92-100. doi: 10.1016/j.jhep.2014.07.034. Epub 2014 Aug 13. Erratum in: J Hepatol. 2016 Mar;64(3):757.

PMID:
25127748

Supplemental Content

Support Center